Zentalis Pharmaceuticals (ZNTL) Receivables - Other (2019 - 2023)

Zentalis Pharmaceuticals' Receivables - Other history runs 5 years deep, the most recent figure standing at $7.9 million for Q1 2023.

• In Q1 2023, Receivables - Other rose 236.8% year-over-year to $7.9 million; the TTM figure through Mar 2023 stood at $7.9 million (up 236.8% YoY), while the FY2022 annual figure was $5.9 million, up 147.53% from the prior year.
• Receivables - Other for Q1 2023 stood at $7.9 million, up from $5.9 million in the prior quarter.
• The five-year high for Receivables - Other was $82.0 million in Q1 2020, with the low at $100000.0 in Q2 2020.
• The 5-year median for Receivables - Other is $2.4 million (2021), against an average of $9.5 million.
• The sharpest annual moves came in 2020 and 2022: Receivables - Other jumped 10150.0% in 2020, then slumped 92.43% in 2022.
• Zentalis Pharmaceuticals' Receivables - Other stood at $200000.0 in 2019, then surged by 155.5% to $511000.0 in 2020, then surged by 364.38% to $2.4 million in 2021, then jumped by 147.53% to $5.9 million in 2022, then jumped by 34.63% to $7.9 million in 2023.
• Business Quant data shows ZNTL's Receivables - Other at $7.9 million in Q1 2023, $5.9 million in Q4 2022, and $3.2 million in Q3 2022.